SLC6A19 Transport Inhibition for Phenylalanine Control in PKU
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for phenylketonuria (PKU), such as enzyme co-factor and enzyme substitution therapy, are not effective for all patients and carry potential adverse events, and there is a need for alternative methods to manage phenylalanine levels to prevent neurological damage.
Innovation Solution
Development of compounds that modulate SLC6A19 transport to regulate amino acid levels, including phenylalanine, through the administration of specific small molecule inhibitors of Formula (I), which can be used to treat or prevent conditions associated with abnormal amino acid levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme co-factor and enzyme substitution therapy are used to treat PKU, then phenylalanine metabolism can be supported, but treatment effectiveness is limited and adverse events may occur
Solution Approach 1:
The patent introduces SLC6A19 as a novel intermediary target - an amino acid transporter in the kidney proximal tubule - to regulate phenylalanine levels. Instead of directly targeting the defective PAH enzyme, the invention uses SLC6A19 inhibitors to modulate amino acid reabsorption, creating an indirect pathway to control blood phenylalanine levels that bypasses the defective metabolic pathway.
Solution Approach 2:
The invention changes the therapeutic parameter from enzyme-based intervention to transporter-based intervention. By targeting SLC6A19 transport function rather than PAH enzyme activity, the treatment approach shifts from restoring deficient metabolic function to actively regulating amino acid levels through an alternative physiological pathway, expanding applicability to patients with various PAH mutation types.
2Reliability
If strict diet control is implemented to manage phenylalanine levels, then neurological damage can be prevented, but quality of life is significantly impacted
Solution Approach 1:
The SLC6A19 inhibitor enables the body's own kidney transport system to self-regulate phenylalanine levels. The drug acts on the endogenous transporter to reduce amino acid reabsorption, allowing physiological self-control of blood phenylalanine levels without requiring external dietary intervention or patient compliance with strict dietary restrictions.
Solution Approach 2:
The invention replaces the mechanical/dietary control system (manual food selection, portion control, and monitoring) with a pharmacological system that directly modulates renal transport. This substitution transforms phenylalanine management from a behavior-dependent process to a physiology-mediated process, reducing the operational burden on patients.
3Adaptability or versatility
If current standard therapies are used, then some patients can be treated, but alternative methods are needed to fully prevent neurological damage
Solution Approach 1:
The SLC6A19 inhibitor provides a universal treatment mechanism that can address phenylalanine elevation regardless of the specific PAH mutation type. By targeting the downstream consequence (amino acid transport) rather than the upstream cause (enzyme deficiency), the therapy achieves multi-functional applicability across different genetic variants while maintaining reliable phenylalanine control.
Solution Approach 2:
Instead of attempting to restore the defective PAH enzyme function (forward approach), the invention inverts the strategy by targeting the compensatory amino acid transport pathway. This reverse approach accepts the enzyme deficiency and instead regulates the alternative pathway (renal reabsorption) to achieve the same protective outcome, expanding treatment effectiveness to all PKU patients.
Data Source
AI summary
Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with abnormal levels of amino acids by modulation of SLC6A19 transport.